



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts

Public declaration of interests

I, **Edward Laane**

Organisation/Company: University of Tartu

Country: Estonia

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
10/2015-02/2016	The Deerfield Institute	Daratumumab	Multiple myeloma
03/2016-03/2016	The Deerfield Institute	CAR-T	
09/2016-09/2016	The Deerfield Institute	Niraparib	Ovarian cancer
09/2016-09/2016	The Deerfield Institute	Rolapitant	Delayed phase chemotherapy-induced nausea and vomiting
09/2016-09/2016	The Deerfield Institute	Neratinib	HER2-positive breast cancer
10/2016-10/2016	The Deerfield Institute	Vosaroxin	Acute myeloid leukemia
10/2016-10/2016	The Deerfield Institute	Xilonix	Advanced colorectal cancer, heavily pre-treated, ECOG 1-2, weight loss
01/2017-01/2017	Novartis Pharma Services Inc. Eesti filiaal	Panobinostat	Multiple Myeloma
11/2017-11/2017	Janssen, UAB "Johnson & Johnson" Estonian branch	Ibrutinib	Waldenstrom's Macroglobulinemia

Classified as public by the European Medicines Agency

2

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

Period	Company	Products	Therapeutic Indication
02/2010-05/2014	Amgen	Romiplostim	ITP, evaluation of bone marrow morphology changes
04/2010-12/2017	German CLL Study Group / Roche	anti-CD20mAb (RO 5072759)	First line CLL patient with comorbidities
06/2011-10/2013	Teva	TL011 (Biosimilar, anti-CD20)	CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma
11/2011-12/2015	Merck	V212 (Vaccine, Herpes Zoster)	Immunocompromised patients with hematologic malignancy
11/2011-12/2017	Roche	Oseltamivir	Immunocompromised patients with hematologic malignancy
07/2012-12/2017	GlaxoSmithkline	Herpes Zoster vaccine GSK 1437173A	Adult autologous haematopoietic stem cell transplant recipients
02/2014-12/2017	Roche	Obinutuzumab	Previously untreated or relapsed/refractory chronic lymphocytic leukemia

2.7 Grant / Funding to organisation /institution

Company	Subject Matter
Novo Nordisk	Hemophilia Rehabilitation Program

2.8 Close family member interest

No interest declared

2.9 Repurposing of a medicinal product

No interest declared

2.10 Any other interests or facts

I do not have or had direct or indirect interests in medical device companies or notified bodies.

2.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Edward Laane
Date:	2022-03-18

For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template